About Damn Time star, Lizzo, revealed she had lost 16 per cent of her body fat over two years in 2025, but now admits her ...

Shares of Hims and Hers Health (NYSE:HIMS) slid 14% in premarket trading following the telehealth company’s announcement of ...

Facebook posts reveal more GI side effects from semaglutide drugs like Ozempic than Mounjaro, offering new insights into ...

Despite a significant revenue drop, Medifast Inc (MED) surpasses guidance and focuses on innovative programs to enhance coach productivity and client engagement.

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

Innovent steps forward with a promising new candidate for obesity and diabetes care. IBI3032 is an orally administered ...

Discover Medifast's Q2 2025 earnings insights, highlighting a business transformation with science-backed health solutions, digital tools, and ...

Shares of Hims & Hers Health fell 13.5% in after-hours trading Monday after the telehealth company missed Wall Street’s ...

The IND application of IBI3032 was accepted by China’s National Medical Products Administration (NMPA) and approved by the U.S. Food and Drug Administration (FDA). A multi-regional Phase 1 clinical ...

Stay updated on Hims & Hers Health Q2 2025 earnings: subscriber growth, global expansion, & personalized care innovation.

Key Points GAAP revenue beat expectations at $105.6 million for Q2 2025 but was down 37.4% year over year. GAAP earnings per share rose to $0.22 for Q2 2025, including a $2.0 million net-of-tax ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...